Recruitment complete in FEVAR study for on-label use with Bentley BeGraft as bridging stent

1710
Eric Verhoeven

Bentley has announced that recruitment is now complete in the fenestrated endovascular aortic aneurysm repair (FEVAR) study that uses the company’s BeGraft peripheral balloon-expandable covered stent as a bridging stent in complex aortic aneurysms. 

Led by Eric Verhoeven (General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany), the open-label study is evaluating the safety and performance of the BeGraft stent as a bridging stent in FEVAR for complex aortic aneurysms. Bentley reports that study has enrolled 100 patients as planned per the study’s protocol.

The company claims that none of the commercially available covered stents are currently indicated as a dedicated bridging stent in FEVAR procedures. The study will bring on-label use in this indication a step closer, Bentley states.

“FEVAR is currently a well-established, minimally-invasive option for patients with abdominal aortic aneurysms and who are not eligible for an open aortic repair,” said Sebastian Büchert (CEO, Bentley). He added: “The use of bridging stents has always been done off-label and we see it as our responsibility to get the BeGraft indicated for those procedures.”

“We already know the patency is very good with the BeGraft as a bridging stent, and we know how to handle this device,” said Verhoeven, who has used bridging stents for over 13 years at his Nuremberg clinic. He states: “Although we have not yet analysed the data, I am not expecting any surprises other than the confirmation that the Bentley BeGraft covered stents do well in this indication.”

The study’s two performance endpoints comprise technical success of the procedure and bridging stent patency after one year. Safety will be evaluated for the one-year time point comprised of the absence of procedure-related complications and bridging stent-related endoleaks. One-year results are expected during the second half of 2023.

Regarding the potential on-label approval of the BeGraft peripheral in this context, Verhoeven said: “If you can use something on-label, many surgeons, particularly in relation to hospital policy, and in relation to the legal ramifications, would not, out of choice, use an off-label product.”

The study is a collaboration between the Foundation for Cardiovascular Research and Education (FCRE, Belgium) and Bentley and is approved by the German competent authority BfArM. German participating centres are the University Hospitals Aachen, University Clinic of Gießen & Marburg, University Clinic Hamburg-Eppendorf, LMU Munich, University Clinic Regensburg, University Heart Center Freiburg-Bad Krozingen, St Franziskus Hospital Münster, Stuttgart Hospital and Nuremberg Hospital.


LEAVE A REPLY

Please enter your comment!
Please enter your name here